Limitations include observed synergistic effects may be specific to certain cell lines, raising concerns about generalizability across different GBM tumor types including GBM tumor cells, organoids, and in vivo models with and without the H3K27M mutation and MGMT gene methylation. This evidence concerns the gene MGMT and glioblastoma.